ZYVERSA THERAPEUTICS, INC. Management Fee Payable
ZYVERSA THERAPEUTICS, INC. (ZVSA) had Management Fee Payable of $3.38 million as of 2021-12-23, per its 10-Q filed 2022-11-14.
Discontinued › Balance Sheet › Liabilities
us-gaap:ManagementFeePayable · last filed 2022-11-14
- 2021-12-23: Management Fee Payable $3.38M.
| Period end | Management Fee Payable |
|---|---|
| 2021-12-23 | $3.38M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |